 Phosphodiesterase 5 Inhibitors
"Phosphodiesterase 5 Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that specifically inhibit PHOSPHODIESTERASE 5.
| Descriptor ID |
D058986
|
| MeSH Number(s) |
D27.505.519.389.735.500
|
| Concept/Terms |
Phosphodiesterase 5 Inhibitors- Phosphodiesterase 5 Inhibitors
- Inhibitors, Phosphodiesterase 5
- Phosphodiesterase Type 5 Inhibitors
- PDE-5 Inhibitors
- Inhibitors, PDE-5
- PDE 5 Inhibitors
- PDE5 Inhibitors
- Inhibitors, PDE5
|
Below are MeSH descriptors whose meaning is more general than "Phosphodiesterase 5 Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Phosphodiesterase 5 Inhibitors".
This graph shows the total number of publications written about "Phosphodiesterase 5 Inhibitors" by people in this website by year, and whether "Phosphodiesterase 5 Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 1 | 2 | | 2010 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2012 | 4 | 0 | 4 | | 2013 | 3 | 0 | 3 | | 2014 | 2 | 3 | 5 | | 2015 | 0 | 1 | 1 | | 2016 | 1 | 0 | 1 | | 2017 | 2 | 0 | 2 | | 2018 | 0 | 1 | 1 | | 2019 | 0 | 1 | 1 | | 2022 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Phosphodiesterase 5 Inhibitors" by people in Profiles.
-
Issapour A, Frank B, Crook S, Hite MD, Dorn ML, Rosenzweig EB, Ivy DD, Krishnan US. Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience. Pediatr Pulmonol. 2022 03; 57(3):724-733.
-
Lane T, Hountras P. A 65-Year-Old Man With Weight Loss, Peripheral Neuropathy, and Lower Extremity Swelling. Chest. 2022 01; 161(1):e29-e34.
-
Cartin-Ceba R, Krowka MJ. Pulmonary Complications of Portal Hypertension. Clin Liver Dis. 2019 11; 23(4):683-711.
-
Mandell EW, Kratimenos P, Abman SH, Steinhorn RH. Drugs for the Prevention and Treatment of Bronchopulmonary Dysplasia. Clin Perinatol. 2019 06; 46(2):291-310.
-
Christie A, Vera PL, Higgins M, Kumar S, Lane M, Preston D. Erectile Dysfunction Medications and Skin Cancer: An Analysis in US Veterans. Urology. 2019 04; 126:116-120.
-
Garcia AM, Nakano SJ, Karimpour-Fard A, Nunley K, Blain-Nelson P, Stafford NM, Stauffer BL, Sucharov CC, Miyamoto SD. Phosphodiesterase-5 Is Elevated in Failing Single Ventricle Myocardium and Affects Cardiomyocyte Remodeling In Vitro. Circ Heart Fail. 2018 09; 11(9):e004571.
-
Sable CA, Ivy DD, Beekman RH, Clayton-Jeter HD, Jenkins KJ, Mahle WT, Morrow WR, Murphy MD, Nelson RM, Rosenthal GL, Stockbridge N, Wessel DL. 2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil. Circ Cardiovasc Qual Outcomes. 2017 07; 10(7).
-
Rashid J, Patel B, Nozik-Grayck E, McMurtry IF, Stenmark KR, Ahsan F. Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH). J Control Release. 2017 03 28; 250:96-106.
-
Humpl T, Berger RMF, Austin ED, Fasnacht Boillat MS, Bonnet D, Ivy DD, Zuk M, Beghetti M, Schulze-Neick I. Treatment initiation in paediatric pulmonary hypertension: insights from a multinational registry. Cardiol Young. 2017 Aug; 27(6):1123-1132.
-
Martin C, Nolen H, Podolnick J, Wang R. Current and emerging therapies in premature ejaculation: Where we are coming from, where we are going. Int J Urol. 2017 01; 24(1):40-50.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|